论文部分内容阅读
目的探讨自体细胞因子诱导的杀伤细胞(CIK)输注联合紫杉醇顺铂方案治疗晚期食管癌的临床疗效。方法将76例晚期食管癌患者随机分为对照组和治疗组,每组38例。对照组患者采用常规紫杉醇顺铂联合方案治疗,治疗组患者采用自体CIK细胞输注与紫杉醇顺铂联合方案治疗。结果治疗组和对照组患者的肿瘤控制率分别为86.9%和63.2%,治疗组的治疗效果明显优于对照组(P<0.05)。治疗组的病情缓解时间以及治疗时间均较对照组显著缩短(P<0.05),治疗后存活时间明显长于对照组(P<0.05),临床死亡率明显低于对照组(P<0.05),治疗期间不良反应发生率明显低于对照组(P<0.05),患者对治疗方案的满意度明显高于对照组(P<0.05)。结论应用自体CIK细胞输注与紫杉醇顺铂联合方案治疗晚期食管癌患者的效果显著。
Objective To investigate the clinical efficacy of autologous cytokine-induced killer (CIK) infusion combined with paclitaxel cisplatin in the treatment of advanced esophageal cancer. Methods 76 patients with advanced esophageal cancer were randomly divided into control group and treatment group, 38 cases in each group. Patients in the control group were treated with the conventional paclitaxel-cisplatin combination regimen. Patients in the treatment group were treated with autologous CIK cell infusion and paclitaxel-cisplatin combination regimen. Results The tumor control rates in the treatment group and the control group were 86.9% and 63.2%, respectively. The therapeutic effect of the treatment group was significantly better than that of the control group (P <0.05). The treatment time and the treatment time were significantly shorter than those in the control group (P <0.05). The survival time of the treatment group was significantly longer than that of the control group (P <0.05), and the clinical mortality was significantly lower than that of the control group (P <0.05) The incidence of adverse reactions was significantly lower than that of the control group (P <0.05). The patients’ satisfaction with the treatment regimen was significantly higher than that of the control group (P <0.05). Conclusion The application of autologous CIK cell infusion combined with paclitaxel in the treatment of advanced esophageal cancer patients with a significant effect.